INSYS Therapeutics Receives FDA Fast Track Designation for Epinephrine Nasal Spray

INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]

Read more...

Analog Devices Share Repurchase Program Increases by $2 Billion

On August 21, Analog Devices, Inc. (ADI) announced that the company’s Board of Directors voted to reinstate their share repurchase program. The company’s existing share repurchase program started in 2004, and Analog Devices has repurchased $5.4 billion in stock since that time. This reinstatement increases the total authorization by an additional $2 billion.   At […]

Read more...

July 2018 Scorecard

The July 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Hemisphere Media Group Announces New Share Repurchase Program

On August 16, Hemisphere Media Group, Inc. (HMTV) announced that its Board of Directors has authorized a new $25 million share repurchase program. The new share repurchase authorization is an addition to the company’s existing $25 million share repurchase program. Hemisphere Media Group is the only U.S. media company solely focusing on the U.S. Hispanic […]

Read more...

China Rapid Finance Announces Stock Repurchase Program

China Rapid Finance Limited (XRF) announced on August 15 that its Board of Directors authorized a new share repurchase program. Under the program, the company can repurchase up to $20 million of its ordinary shares in the form of American depository shares. China Rapid Finance is one of China’s largest consumer lending marketplaces.   Sonal […]

Read more...

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

Read more...

Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Sonal alerted […]

Read more...

Leidos Awarded $365 Million by Department of Energy

On July 25, Leidos (LDOS) announced that the company has been awarded a Department of Energy contract to support research for the National Energy Technology Laboratory (NETL). The contract has a three-year base performance period followed by two optional contract periods. It has the potential to extend 10 years for a total valuation of $364.7 […]

Read more...